WO2012141256A1 - Procédé d'activation d'une bonne bactérie intestinale et composition pour l'activation d'une bonne bactérie intestinale - Google Patents

Procédé d'activation d'une bonne bactérie intestinale et composition pour l'activation d'une bonne bactérie intestinale Download PDF

Info

Publication number
WO2012141256A1
WO2012141256A1 PCT/JP2012/060048 JP2012060048W WO2012141256A1 WO 2012141256 A1 WO2012141256 A1 WO 2012141256A1 JP 2012060048 W JP2012060048 W JP 2012060048W WO 2012141256 A1 WO2012141256 A1 WO 2012141256A1
Authority
WO
WIPO (PCT)
Prior art keywords
oligosaccharides
good
raffinose
activating
bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2012/060048
Other languages
English (en)
Japanese (ja)
Inventor
勝寿 木下
麻子 堀川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KITANOTATSUJIN CO Ltd
Original Assignee
KITANOTATSUJIN CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KITANOTATSUJIN CO Ltd filed Critical KITANOTATSUJIN CO Ltd
Priority to JP2013509964A priority Critical patent/JP6328422B2/ja
Publication of WO2012141256A1 publication Critical patent/WO2012141256A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Definitions

  • the present invention relates to a method for activating good enterobacteria, a method for improving intestinal flora by activating good enterobacteria, and an enteric good bacteria activating composition.
  • Intestinal bacteria that are permanently present in the human intestine have an important relationship with human health.
  • Bifidobacteria which is a representative of enterobacterium good bacteria, is known to have an intestinal action such as prevention and treatment of diarrhea and constipation, and an effect of inhibiting the growth of harmful bacteria in the intestine.
  • the proportion of various intestinal flora in the intestinal flora varies from individual to individual, and also varies depending on factors such as age, nutritional components, and stress.
  • bifidobacteria tend to decrease due to disease and aging
  • Conventionally there is a method of ingesting bifidobacteria in foods obtained by adding bifidobacteria to dairy products.
  • bifidobacteria are ingested orally, it is difficult to supply the bifidobacteria that have survived to the intestines, and the desired intestinal regulation effect cannot always be sufficiently obtained in many cases.
  • Patent Document 1 discloses a bread containing an oligosaccharide.
  • Patent Document 2 discloses a feed containing raffinose.
  • oligosaccharides have common properties such as being not degraded by human digestive enzymes, not being absorbed from the intestinal tract, and being selectively assimilated by bifidobacteria. However, these oligosaccharides are not necessarily selectively used only for good bacteria such as bifidobacteria, and there are bad bacteria that proliferate using oligosaccharides. When each of the above oligosaccharides is added to food or the like and taken orally, the oligosaccharides have only exhibited their characteristics. In addition, there are individual differences in which oligosaccharides exert the intestinal regulating effect, and ingestion of unsuitable oligosaccharides may cause side effects such as diarrhea.
  • oligosaccharides vary greatly in the degree of utilization by good bacteria and bad bacteria depending on the type thereof, and a satisfactory improvement effect on intestinal bacterial flora may not always be obtained.
  • the actual situation is that a method for improving the intestinal microflora having individual differences and obtaining a highly effective intestinal regulating action has not been established.
  • an object of the present invention is to provide a method for activating good enterobacteria and a composition for activating good enterobacteria to improve the intestinal flora.
  • the present invention relates to the following inventions.
  • ⁇ 1> Select a plurality of oligosaccharides suitable for the activation of the beneficial enteric bacteria, and combine the plurality of oligosaccharides at a blending ratio suitable for the activation of the enteric good bacteria to give to the intestinal flora A method for activating good intestinal bacteria.
  • ⁇ 2> The intestine according to ⁇ 1>, wherein the plurality of oligosaccharides are two or more selected from the group consisting of lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltooligosaccharide, and galactooligosaccharide. How to activate Uchizen good bacteria.
  • ⁇ 3> The method for activating good enterobacteria according to ⁇ 1>, wherein the plurality of oligosaccharides is a combination of lactose, raffinose and cellooligosaccharide.
  • ⁇ 4> The method for activating good enterobacteria according to ⁇ 1>, wherein the plurality of oligosaccharides is a combination of raffinose, lactulose and cellooligosaccharide.
  • ⁇ 5> The method for activating good enterobacteria according to ⁇ 1>, wherein the plurality of oligosaccharides is a combination of lactose, raffinose, lactulose and cellooligosaccharide.
  • ⁇ 6> The method for activating good enteric bacteria according to ⁇ 1>, wherein the plurality of oligosaccharides are lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltoligosaccharide, and galactooligosaccharide.
  • An intestine containing a mixture of a plurality of oligosaccharides suitable for activating good enteric bacteria in a target, and a combination of the plurality of oligosaccharides combined in a proportion suitable for activating the enteric good bacteria A good bacteria activation composition.
  • oligosaccharides are two or more selected from the group consisting of lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltooligosaccharide, and galactooligosaccharide.
  • Uchizen good bacteria activation composition Uchizen good bacteria activation composition.
  • the plurality of oligosaccharides is a combination of lactose, raffinose, lactulose, and cellooligosaccharide.
  • oligosaccharides are lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltoligosaccharide, and galactooligosaccharide.
  • the activation method of the enterobacterium good bacteria which can obtain the improvement effect with respect to the intestinal microflora from which environment differs according to individual differences, physical condition, age, etc., and an enterobacterium good bacteria activation composition Is done.
  • the method for activating good enteric bacteria of the present invention selects a plurality of oligosaccharides suitable for the activation of good enteric bacteria, and the blending ratio of the plurality of oligosaccharides suitable for the activation of the good enteric bacteria It is characterized by being given to the intestinal flora in combination.
  • the composition for activating good enteric bacteria of the present invention uses the above-mentioned method for activating good enteric bacteria, selects a plurality of oligosaccharides suitable for activating the target enteric good bacteria, It is characterized by containing the mixture which combined these oligosaccharides with the mixture ratio suitable for activation of the said enteric good bacteria.
  • the “intestinal good bacteria” are useful microorganisms in the human digestive tract, and specific examples include bifidobacteria and lactic acid bacteria.
  • the method for activating enteric good bacteria in the present invention is particularly bifidos. Suitable for activating bacteria.
  • the method for activating the enteric good bacteria is based on the original theory EOS theory developed by the present inventors.
  • the EOS theory uses Enterobacteria Oligosaccharide Synergy, and more specifically, it is the optimal bifidobacterial growth factor for the type of bifidobacteria that is representative of useful bacteria in the intestinal flora. This is a theory that creates a synergistic effect by selecting and mixing various oligosaccharides and maximizing the growth effect of the entire bifidobacteria.
  • the oligosaccharides complement each other, and the bifidobacteria inhabiting the intestine are used without waste, which is more effective than using the oligosaccharide alone.
  • the intestinal bacterial flora including other enteric good bacteria such as other bifidobacteria and lactic acid bacteria
  • this effect is not recognized in the human intestine in the combination of saccharides that do not include the oligosaccharide that is the subject of the present invention, such as glucose and sucrose, and is unique to the combination of a plurality of oligosaccharides based on the EOS theory. It is an effect. Therefore, taking or ingesting multiple oligosaccharides based on the method of activating good enterobacterium in EOS theory is very effective in that it can be used safely and with little risk of side effects. .
  • the oligosaccharide that can be used in the present invention is not particularly limited.
  • a commercially available product can be used, or a purified product separated and purified from an extract of a natural product containing the oligosaccharide can be used.
  • These oligosaccharides may be in any form such as powder, liquid or syrup, but are usually powder or syrup from the viewpoint of handling.
  • oligosaccharides since the effect of improving the intestinal microflora is particularly recognized, 2 selected from the group consisting of lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltoligosaccharide and galactooligosaccharide 2 It is preferable to use more than one species. These oligosaccharides reach the intestine without being digested and absorbed in the human digestive tract, and are highly effective in proliferating good intestinal bacteria (bifidobacteria, lactic acid bacteria, etc.).
  • oligosaccharides The selection and blending ratio of oligosaccharides are determined based on the EOS theory.
  • raffinose has a high ratio of giving an intestinal regulating action to a subject. Therefore, it is preferable to include raffinose, and it has no ability to assimilate raffinose or has a weak ability to assimilate raffinose.
  • raffinose as a base, when the total amount is 100 wt%, raffinose is 1 wt% to 80 wt% (preferably 3 to 60 wt%), and other oligosaccharides are 70 wt% to 99% by weight (preferably 40 to 97% by weight).
  • a suitable combination of oligosaccharides to which the EOS theory can be applied is a combination of lactose, raffinose and cellooligosaccharide.
  • oligosaccharide combinations to which the EOS theory can be applied are raffinose, lactulose and cellooligosaccharide combinations.
  • oligosaccharide combinations to which the EOS theory can be applied are combinations of lactose, raffinose, lactulose and cellooligosaccharide.
  • oligosaccharide combinations to which the EOS theory can be applied are combinations of lactose, raffinose, lactulose, cellooligosaccharides, xylooligosaccharides, fructooligosaccharides, isomaltoligosaccharides and galactooligosaccharides.
  • the method for activating good enteric bacteria of the present invention may be performed by ingesting each of the plurality of oligosaccharides so that they can be supplied into the intestine almost simultaneously. It is carried out by taking and ingesting as a composition for activating enteric good bacteria of the present invention comprising a mixture of a plurality of oligosaccharides combined at a blending ratio suitable for activating good enteric bacteria.
  • the intestinal good bacteria activating composition of the present invention comprises the above-mentioned oligosaccharides (particularly selected from the group consisting of lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltoligosaccharide and galactooligosaccharide)
  • oligosaccharides particularly selected from the group consisting of lactose, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltoligosaccharide and galactooligosaccharide
  • the above is contained in a combination ratio suitable for the activation of good enterobacteria (especially bifidobacteria) based on EOS theory.
  • composition for activating the enteric good bacteria is a combination of lactose, raffinose and cellooligosaccharide.
  • An example of a suitable amount of this combination is 28 to 35% by weight of lactose, 48 to 55% by weight of raffinose and 18 to 25% by weight of cellooligosaccharide.
  • Another preferred intestinal good fungus activating composition formulation is a combination of raffinose, lactulose and cellooligosaccharide.
  • An example of a suitable amount of this combination is raffinose 48 to 55% by weight, lactulose 8 to 15% by weight and cellooligosaccharide 38 to 45% by weight.
  • composition for activating the enteric good bacteria are a combination of lactose, raffinose, lactulose and cellooligosaccharide.
  • An example of a suitable blending amount of this combination is 8 to 15% by weight of lactose, 60 to 65% by weight of raffinose, 21 to 25% by weight of lactulose and 3 to 11% by weight of cellooligosaccharide.
  • the plurality of oligosaccharides is a combination of lactose 8, raffinose, lactulose, cellooligosaccharide, xylooligosaccharide, fructooligosaccharide, isomaltoligosaccharide and galactooligosaccharide .
  • lactose 8-12% lactose 8-12%, raffinose 4-6%, lactulose 8-12%, cellooligosaccharide 20-25%, xylooligosaccharide 1-4%, fructooligosaccharide 28 to 32% by weight, isomalt-oligosaccharides 8 to 12% by weight and galactooligosaccharides 8 to 12% by weight.
  • the EOS theory is suitably applied, and an improvement effect is recognized even for the intestinal flora in which the environment varies depending on individual differences, physical condition, age, and the like.
  • the enteric good bacteria active composition of this invention may contain the other additive as needed.
  • the addition amount of other additives is arbitrary as long as the object of the present invention is not impaired.
  • Other additives include, but are not limited to, sugars other than oligosaccharides (such as sucrose), preservatives, colorants, excipients, excipients, hygroscopic agents, and the like.
  • enteric good bacteria (especially bifidobacteria) activation composition of the present invention is not particularly limited, and powders, granules, tablets, capsules, enteric solvents, troches, liquids for internal use, liquids for external use, suspensions, Any form of emulsion, syrup, etc. may be used.
  • the method for producing the enteric good bacteria activating composition of the present invention is not particularly limited, and varies depending on the dosage form, but can be produced and processed by conventional methods conventionally used in various fields.
  • auxiliary agents such as an excipient, a binder, a disintegrant, a lubricant, a corrigent, and a stabilizer may be used depending on the purpose.
  • the intestinal good bacteria activating composition of the present invention can be used as it is, or can be blended in various foods and health functional foods (hereinafter collectively referred to as “foods”).
  • the blending amount is not particularly specified and is arbitrary, and is appropriately determined in consideration of the type and quality of food.
  • blended the enteric good bacteria active composition of this invention contain the component used for foodstuffs, a functional food ingredient, and a food additive within the range which does not impair the effect of this invention. It may be.
  • the intake amount of the composition for activating good enteric bacteria of the present invention varies depending on the state of the intestinal flora, age, weight, symptom, dosage form, etc. In the case of high purity blended powder, it is about 3 to 10 g per day.
  • the oligosaccharides used are as follows. ⁇ Lactose (Replino Foods) ⁇ Raffinose (manufactured by Nippon Beet Sugar Co., Ltd.) ⁇ Lactulose (Morinaga Milk Industry) -Cellooligosaccharide (Nippon Paper Chemicals) ⁇ Xylooligosaccharide (Suntory) ⁇ Fructooligosaccharide (Meiji Food Materia) ⁇ Isomaltooligosaccharide (made by Showa Sangyo Co., Ltd.) ⁇ Galactooligosaccharide (Nisshin Sugar Co., Ltd.) ⁇ Sucrose (manufactured by Nippon Beet Sugar Co., Ltd.)
  • Reference Example 1 Preparation of composition
  • the composition of Reference Example 1 was prepared according to the following procedure.
  • the raffinose component was separated from beet molasses with a chromatographic separator, concentrated, purified and crystallized, and then dried to obtain powdered raffinose.
  • a predetermined amount of sucrose was added to powdered raffinose, mixed well, and granulated to obtain a composition of Reference Example 1 containing 98% by weight raffinose and 2% by weight sucrose.
  • Example 1 (1) Preparation of composition The composition of Example 1 was prepared according to the following procedure. The composition of Example 1 containing 30% by weight of lactose, 50% by weight of raffinose, and 20% by weight of cellooligosaccharide was obtained by thoroughly mixing 600 g of lactose, 1000 g of raffinose and 400 g of cellooligosaccharide until uniform. .
  • Example 2 (1) Preparation of composition
  • the composition of Example 2 was prepared according to the following procedure.
  • a composition of Example 2 containing 50% by weight of raffinose, 10% by weight of lactulose, and 40% by weight of cellooligosaccharide was obtained by thoroughly mixing 1000 g of raffinose, 200 g of lactulose and 800 g of cellooligosaccharide until uniform. .
  • Example 3 (1) Preparation of composition
  • the composition of Example 3 was prepared according to the following procedure. 200 g of lactose, 1240 g of raffinose, 460 g of lactulose and 100 g of cellooligosaccharide are mixed thoroughly until uniform, and then granulated to produce 10 wt% lactose, 62 wt% raffinose, 23 wt% lactulose, 5 wt% cellooligosaccharide The composition of Example 3 was obtained.
  • Example 4 (1) Preparation of composition The composition of Example 4 was prepared according to the following procedure. 100 g of lactose, 49 g of raffinose, 100 g of lactulose, 230 g of cellooligosaccharide, 20 g of xylooligosaccharide, 300 g of fructooligosaccharide, 100 g of isomaltoligosaccharide, 100 g of galactooligosaccharide and 1 g of sucrose are mixed well until granulated, and granulated.
  • Example 4 Wt%, raffinose 4.9 wt%, lactulose 10 wt%, cellooligosaccharide 23 wt%, xylooligosaccharide 2 wt%, fructooligosaccharide 30 wt%, isomaltoligosaccharide 10 wt%, galactooligosaccharide 10 wt%, sucrose 0.
  • the composition of Example 4 containing 1% by weight was obtained.
  • (2) Evaluation The composition of Example 4 was ingested by 5 persons (3 males and 2 females) with constipation for 5 g / day a week. Carried out. As a result, 4 out of 5 responded that the number of stools was improved compared to when they were not ingested. Two people in particular also showed changes in the amount of increase.
  • the present invention it is possible to obtain an improvement effect on the intestinal bacterial flora whose environment varies depending on individual differences, physical condition, age, and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé pour l'activation d'une bonne bactérie intestinale dans le but d'améliorer la flore bactérienne intestinale. Ledit procédé consiste à sélectionner de nombreux oligosaccharides qui conviennent à l'activation d'une bonne bactérie intestinale d'intérêt, à combiner les nombreux oligosaccharides à un rapport de concentration adapté à l'activation de la bonne bactérie intestinale, et à administrer la combinaison résultante à une flore bactérienne intestinale. Le procédé d'activation d'une bonne bactérie intestinale peut obtenir un effet améliorant d'une flore bactérienne intestinale pour laquelle l'environnement est modifié en fonction des individus, de la condition physique, de l'âge et analogue.
PCT/JP2012/060048 2011-04-15 2012-04-12 Procédé d'activation d'une bonne bactérie intestinale et composition pour l'activation d'une bonne bactérie intestinale Ceased WO2012141256A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013509964A JP6328422B2 (ja) 2011-04-15 2012-04-12 腸内善玉菌活性化組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011091362 2011-04-15
JP2011-091362 2011-04-15

Publications (1)

Publication Number Publication Date
WO2012141256A1 true WO2012141256A1 (fr) 2012-10-18

Family

ID=47009423

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/060048 Ceased WO2012141256A1 (fr) 2011-04-15 2012-04-12 Procédé d'activation d'une bonne bactérie intestinale et composition pour l'activation d'une bonne bactérie intestinale

Country Status (2)

Country Link
JP (2) JP6328422B2 (fr)
WO (1) WO2012141256A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105535580A (zh) * 2015-12-21 2016-05-04 上海善力健生物科技有限公司 一种用于改善人体肠道菌群的生物制剂及其制备方法
JP2017502701A (ja) * 2014-01-16 2017-01-26 アルヴィンド マリナース ラリ、 農業廃棄物からのオリゴ糖の分画方法
JP2021536227A (ja) * 2018-08-15 2021-12-27 ケンブリッジ グリコサイエンス エルティーディー 新規組成物、それらの使用、およびそれらの形成方法
JP2022534154A (ja) * 2020-04-29 2022-07-28 ネオ クレマー カンパニー リミテッド ガラクトオリゴ糖、又はガラクトオリゴ糖及びコラーゲントリペプチドを含む免疫機能改善及び皮膚状態改善用の機能性食品組成物及び化粧料組成物
US11771123B2 (en) 2019-08-16 2023-10-03 Cambridge Glycoscience Ltd Methods for treating biomass to produce oligosaccharides and related compositions
JP2023164630A (ja) * 2016-07-07 2023-11-10 株式会社東洋新薬 経口組成物
US11871763B2 (en) 2019-12-12 2024-01-16 Cambridge Glycoscience Ltd Low sugar multiphase foodstuffs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10175867A (ja) * 1996-12-12 1998-06-30 Morinaga Milk Ind Co Ltd ビフィズス菌増殖促進組成物及びその用途
JP2007330177A (ja) * 2006-06-16 2007-12-27 Asahi Kasei Chemicals Corp 腸内細菌賦活剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10175867A (ja) * 1996-12-12 1998-06-30 Morinaga Milk Ind Co Ltd ビフィズス菌増殖促進組成物及びその用途
JP2007330177A (ja) * 2006-06-16 2007-12-27 Asahi Kasei Chemicals Corp 腸内細菌賦活剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ASAKO HORIKAWA: "Oligo-To Kongobutsu ni yoru Benpi no Kanwa", JOURNAL OF JAPAN SOCIETY FOR LACTIC ACID BACTERIA, vol. 22, no. 2, 1 July 2011 (2011-07-01), pages 135 *
YOSHIYUKI MORISHITA: "Dietary Components Responsible for the Stability and Alteration of the Intestinal Microflora (2)", JOURNAL OF INTESTINAL MICROBIOLOGY, vol. 12, no. 2, 1999, pages 57 - 72 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502701A (ja) * 2014-01-16 2017-01-26 アルヴィンド マリナース ラリ、 農業廃棄物からのオリゴ糖の分画方法
CN105535580A (zh) * 2015-12-21 2016-05-04 上海善力健生物科技有限公司 一种用于改善人体肠道菌群的生物制剂及其制备方法
JP2023164630A (ja) * 2016-07-07 2023-11-10 株式会社東洋新薬 経口組成物
JP7588892B2 (ja) 2016-07-07 2024-11-25 株式会社東洋新薬 経口組成物
JP2021536227A (ja) * 2018-08-15 2021-12-27 ケンブリッジ グリコサイエンス エルティーディー 新規組成物、それらの使用、およびそれらの形成方法
JP7374991B2 (ja) 2018-08-15 2023-11-07 ケンブリッジ グリコサイエンス エルティーディー 新規組成物、それらの使用、およびそれらの形成方法
US11903399B2 (en) 2018-08-15 2024-02-20 Cambridge Glycoscience Ltd Compositions, their use, and methods for their formation
US12239152B2 (en) 2018-08-15 2025-03-04 Cambridge Glycoscience Ltd Compositions, their use, and methods for their formation
US11771123B2 (en) 2019-08-16 2023-10-03 Cambridge Glycoscience Ltd Methods for treating biomass to produce oligosaccharides and related compositions
US11871763B2 (en) 2019-12-12 2024-01-16 Cambridge Glycoscience Ltd Low sugar multiphase foodstuffs
JP2022534154A (ja) * 2020-04-29 2022-07-28 ネオ クレマー カンパニー リミテッド ガラクトオリゴ糖、又はガラクトオリゴ糖及びコラーゲントリペプチドを含む免疫機能改善及び皮膚状態改善用の機能性食品組成物及び化粧料組成物
JP7212410B2 (ja) 2020-04-29 2023-01-25 ネオ クレマー カンパニー リミテッド ガラクトオリゴ糖、又はガラクトオリゴ糖及びコラーゲントリペプチドを含む免疫機能改善及び皮膚状態改善用の機能性食品組成物及び化粧料組成物

Also Published As

Publication number Publication date
JPWO2012141256A1 (ja) 2014-07-28
JP2018138580A (ja) 2018-09-06
JP6328422B2 (ja) 2018-05-23

Similar Documents

Publication Publication Date Title
JP2018138580A (ja) 腸内善玉菌の活性化方法
US20040161422A1 (en) Nutritional compositions comprising probiotics
JP4451879B2 (ja) イソマルトのプレバイオティクスとしての使用
US20030166610A1 (en) Nutritional composition
US20100322904A1 (en) Composition comprising bifidobacterium infantis and fructo- and galacto-oligosaccharides for the prevention of intestinal discomfort in infants
CN103068254A (zh) 合生素产品
JP2013209396A (ja) 腎臓機能を増大させるための組成物および方法
EP2014181A2 (fr) Compositions basées sur des ingrédients prébiotiques et immunogéniques pour la prévention et le traitement de troubles gastroentériques provoqués par le dysbiosis et/ou des altérations de la flore intestinale normale
JP6960988B2 (ja) インスリン抵抗性の悪化予防または改善剤
CN101410101A (zh) 抗脂肪沉积用组合物
Sharma et al. Miraculous health benefits of prebiotics
KR100424660B1 (ko) 비타민강화 바실러스 폴리퍼멘티쿠스(Bacillus polyfermenticus) KCCM 10104 함유 정장기능성 영양식품 조성물
KR20050105669A (ko) 유산균 조성물
de Figueiredo et al. Advances and new perspectives in prebiotic, probiotic and symbiotic products for food nutrition and feed
WO2023205762A9 (fr) Procédés et compositions pour ralentir le développement du diabète ou réduire un risque de diabète
US8993639B2 (en) Compound and method for treatment of gastroesophageal reflux
CA3157496A1 (fr) Compositions de fibres alimentaires avec du psyllium et procedes d'utilisation
A Radwan et al. Effect of probiotic fermented camel milk containing oat milk on hyperglycemia in streptozotocin-induced diabetic rats
JP2003334025A (ja) 健康食品
Galiulin Sugars and beyond. The role of sugars and the other nutrients and their potential impact on caries
WO2026090587A1 (fr) Compositions synbiotiques pour dysbiose intestinale
Fu et al. Efficacy and safety of xylooligosacchrides
JP6112493B2 (ja) 組成物
JP2003334028A (ja) 健康食品
DE102011012494A1 (de) Prebiotische Kohlenhydrat-Zusammensetzungen

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12770857

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2013509964

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12770857

Country of ref document: EP

Kind code of ref document: A1